Lotus Bio-Technology Development (LBTD) Ratios
Lotus Bio-Technology Development Ratios
LBTD's free cash flow for Q3 2018 was $-1.48K. For the 2018 fiscal year, LBTD's free cash flow was increased by $0.00 and operating cash flow was $-1.48K. See a summary of the company’s cash flow.
| Ratios | Mar 17 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Cash Ratio | 0.00 |
| Solvency Ratio | -0.23 |
| Operating Cash Flow Ratio | -0.22 |
| Short-Term Operating Cash Flow Coverage | -2.75 |
| Net Current Asset Value | $ -80.86K |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.00 |
| Debt-to-Equity Ratio | -0.11 |
| Debt-to-Capital Ratio | -0.12 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | 0.00 |
| Debt Service Coverage Ratio | -121.10 |
| Interest Coverage Ratio | 0.00 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.00 |
| Net Debt to EBITDA | -0.33 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 100.00% |
| Return on Assets (ROA) | 0.00% |
| Return on Equity (ROE) | 31.89% |
| Return on Capital Employed (ROCE) | 24.18% |
| Return on Invested Capital (ROIC) | 28.35% |
| Return on Tangible Assets | 0.00% |
| Earnings Yield | -0.17% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -0.00 |
| Free Cash Flow Per Share | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 |
| Operating Cash Flow Coverage Ratio | -2.75 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -0.15% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -592.76 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -189.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -652.69 |
| Price-to-Operating Cash Flow Ratio | -652.69 |
| Price-to-Earnings Growth (PEG) Ratio | 6.06 |
| Enterprise Value Multiple | -593.09 |
| Enterprise Value | 11.59M |
| EV to EBITDA | -593.09 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -653.05 |
| EV to Operating Cash Flow | -653.05 |
| Tangible Book Value Per Share | -0.00 |
| Shareholders’ Equity Per Share | -0.00 |
| Tax and Other Ratios | |
| Effective Tax Rate | -38.95 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -0.00 |
| Tax Burden | 1.00 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.91 |
Currency in USD
